Capsular and Intra-articular Corticosteroid Injection for Frozen Shoulder

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Oslo University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT00840229
First received: February 8, 2009
Last updated: June 24, 2011
Last verified: June 2011

February 8, 2009
June 24, 2011
February 2009
December 2011   (final data collection date for primary outcome measure)
Pain reduction [ Time Frame: 2-3 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00840229 on ClinicalTrials.gov Archive Site
Function (ROM, SPADI, Constant score) Life quality [ Time Frame: 2-3 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Capsular and Intra-articular Corticosteroid Injection for Frozen Shoulder
Capsular and Intra-articular Corticosteroid Injection for Adhesive Capsulitis (Frozen Shoulder): a Randomised, Double Blind, Placebo Controlled Trial

The purpose of this study is to compare ultrasound guided capsular corticosteroid injection into the rotator interval/anterior capsule and the GH joint with ultrasound guided corticosteroid injection into the GH joint only. Both methods will be compared with placebo injections.

Primary outcome measure: pain reduction Secondary outcome measures: improvement of function (SPADI, Constant score, Life quality, ROM).

0-hypothesis: no difference between the methods.

The investigators want to find out if the clinical effect of the combined capsular and intra-articular injections are better than placebo and better that intra-articular injections

3 groups, 50 patients in each, follow-up visits after 3, 6, 12 and 26 weeks.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Adhesive Capsulitis
  • Drug: lidocaine
    6 ml 10 mg/ml
  • Drug: triamcinolone
    1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
  • Experimental: 1 capsular & intra-articular
    corticosteroid injection in capsule and intra-articular
    Intervention: Drug: triamcinolone
  • Active Comparator: 2 intra-articular
    corticosteroid injection intra-articular placebo injection in capsule
    Intervention: Drug: triamcinolone
  • Placebo Comparator: 3 placebo
    placebo injections in capsule and intra-articular
    Intervention: Drug: lidocaine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
150
December 2012
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pain and stiffness in one shoulder 1 - 6 months
  • Restriction of passive ROM; > 50 % reduced external rotation compared to other shoulder, capsular pattern according to Cyriax

Exclusion Criteria:

  • Systemic inflammatory disease
  • Corticosteroid treatment last 3 months
  • Poorly controlled Diabetes mellitus
  • Pregnancy
  • Contraindications/allergy to corticosteroids and/or Lidocaine
  • Severe infections
  • Osteoarthritis of the shoulder
  • Fractures of the shoulder
  • Rotator cuff pathology causing pain or disability
  • Fibromyalgia
  • Not able to understand Norwegian
Both
25 Years to 70 Years
No
Contact: Tore A. Prestgaard, MD 33134000 Tore.Prestgaard@rehabilitering.net
Contact: Simen Haugen, MD 33134000 Simen.Haugen@rehabilitering.net
Norway
 
NCT00840229
S-08546, REK, Interne tjenester, IT-avdelingen, Rikshospitalet HF
No
Tore A. Prestgaard, MD, Vestfold Hospital Trust, Clinic Physical Medicine and Rehabilitaion
Oslo University Hospital
Not Provided
Principal Investigator: Tore A Prestgaard, MD Vestfold Hospital Trust
Oslo University Hospital
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP